Michel Vounatsos, Biogen CEO (via YouTube)

June 10, 2022 12:07 PM EDTUpdated 01:23 PM

Biogen yanks its Aduhelm application in Canada, days after celebrating the drug's 1-year anniversary in the US

Nicole DeFeudis

Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Is there still hope for Summit's cancer drug buried in the data?

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

EMA considers serious eye condition a ‘very rare’ side effect of semaglutide

Regeneron makes $80M obesity deal with Hansoh

At a crossroads, biotechs are passing on reverse mergers in 2025

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...